Results 71 to 80 of about 379,801 (144)

Breakthrough SARS-CoV-2 Omicron Variant in Individuals Primed with Heterologous Vaccines Enhances Inhibition Performance of Neutralizing Antibody to BA.2 Parental Lineage

, 2023
This study aims to analyze the neutralization ability against Omicron parental variants in five clusters of individuals with different Coronavirus disease (COVID-19) immunity backgrounds, including individuals receiving a homologous or heterologous ...
Teerapat Nualnoi, Theerakamol Pengsakul, Jidapa Szekely, Paweena Wongwitwichot, Panuttha Chaimuti, Natthaphon Nanakorn, Namchoke Somapa, Denpong Somapa, Piyawut Swangphon   +8 more
core   +1 more source

BNT162b2-boosted immune responses six months after heterologous or homologous ChAdOx1nCoV-19/BNT162b2 vaccination against COVID-19

, 2022
Heterologous prime/boost vaccination with a vector-based approach (ChAdOx-1nCov-19, ChAd) followed by an mRNA vaccine (e.g. BNT162b2, BNT) has been reported to be superior in inducing protective immunity compared to repeated application of the same ...
Odak, Ivan, Ramos, Gema Morillas, Dopfer-Jablonka, Alexandra, Behrens, Georg M. N., Cossmann, Anne, Stankov, Metodi V., Köhler, Miriam, Hetzel, Laura, Förster, Reinhold, Barros-Martins, Joana, Patzer, Gwendolyn   +10 more
core   +1 more source

The influence of previous exposure to environmental mycobacteria on the interferon-gamma response to bacille Calmette-Guérin vaccination in southern England and northern Malawi.

, 2006
We report a large study of the effect of BCG vaccination on the in vitro 6-day whole blood interferon-gamma (IFN-gamma) response to antigens from eight species of mycobacteria among schoolchildren in south-eastern England, where bacille Calmette-Guérin ...
Crampin, A.C., Nazareth, B., Stenson, S, Branson, K, Floyd, S., Weir, RE, Branson, K., Fine, P.E.M., Sichali, L., Chaguluka, SD, Chaguluka, S.D., Donovan, L., Weir, R.E., Stanley, C., Donovan, L, Black, G.F., Nazareth, B, Stenson, S., Dockrell, H.M., Sichali, L, Crampin, AC, Dockrell, HM, Black, GF, Stanley, C, Fine, PEM, Floyd, S   +25 more
core   +1 more source

Comparing Antibody Responses to Homologous vs. Heterologous COVID-19 Vaccination: A Cross-Sectional Analysis in an Urban Bangladeshi Population

Background: Vaccination has played a crucial role in mitigating the spread of COVID-19 and reducing its severe outcomes. While over 90% of Bangladesh’s population has received at least one COVID-19 vaccine dose, the comparative effectiveness of ...
Bharati Rani Roy, Mustufa Mahmud, Md. Nasir Ahmed Khan, Anjan Kumar Roy, Md. Safiqul Islam, Fablina Noushin, Goutam Kumar Dutta, Md. Nazmul Islam, Protim Sarker, Kazi Istiaque Sanin, Abir Dutta, Mahbub Elahi, Md. Khaledul Hasan, Mansura Khanam, Nuzhat Nadia, Azizur Rahman Sharaque, Fahmida Tofail   +16 more
core   +1 more source

Failure of vaccination to prevent outbreaks of foot-and-mouth disease [PDF]

, 1996
Outbreaks of foot-and-mouth disease persist in dairy cattle herds in Saudi Arabia despite revaccination at intervals of 4-6 months. Vaccine trials provide data on antibody responses following vaccination.
Woolhouse, Mark E; id_orcid, Pearson, A., Kitching, R.P., Haydon, D T   +3 more
core   +1 more source

Heterologous ChAdOx1-BNT162b2 vaccination in a Korean cohort induces a robust genetic immune and antibody response that includes Omicron

, 2022
Heterologous ChAdOx1-BNT162b2 vaccination induces a stronger immune response than two doses of BNT162b2. Yet, the molecular transcriptome, the germline allelic variants of immunoglobulin loci and anti-Omicron antibody levels induced by the heterologous ...
Lee, H (via Mendeley Data), Lee, Hye Kyung   +1 more
core   +1 more source

Humoral Response Induced by Prime-Boost Vaccination with the ChAdOx1 nCoV-19 and mRNA BNT162b2 Vaccines in a Teriflunomide-Treated Multiple Sclerosis Patient

, 2021
Patients with multiple sclerosis (MS) are treated with drugs that may impact immune responses to SARS-CoV-2 vaccination. Evaluation of “prime-boost” (heterologous) vaccination regimens including a first administration of a viral vector-based vaccine and ...
Yves Michiels, Jérôme Berger, Kohli, E., Evelyne Kohli, Berger, J., Michiels, Y., Collin, G., Gilles Collin, Houhou-Fidouh, N., Nadhira Houhou-Fidouh   +9 more
core   +1 more source

Heterologous prime-boost vaccination protects against EBV antigen–expressing lymphomas [PDF]

, 2019
The Epstein-Barr virus (EBV) is one of the predominant tumor viruses in humans, but so far no therapeutic or prophylactic vaccination against this transforming pathogen is available.
Taylor, Graham S, Taylor, Graham S., Citterio, C, Leung, Carol S, Taylor, Graham, Dzionek, A, Rühl, Julia, Dzionek, Andrzej, Wilson, Joanna B, Engelmann, Christine, Leung, Carol S., Dreyer, J, Wilson, Joanna B., Dreyer, Johannes, Leung, C, Khanna, Rajiv, Haigh, Tracey, Citterio, Carmen, Wilson, J, Munz, Christian, Münz C, Khanna R, Citterio C, Wilson JB, Dzionek A, Taylor GS, Engelmann C, Rühl J, Leung CS, Dreyer J, Haigh T   +30 more
core   +1 more source

Homologous or heterologous administration of mRNA or adenovirus-vectored vaccines show comparable immunogenicity and effectiveness against the SARS-CoV-2 Omicron variant

Expert Review of Vaccines
Background Heterologous prime-boost schedules have been employed in SARS-CoV-2 vaccination, yet additional data on immunogenicity and effectiveness are still needed.Research design and methods Here, we measured the immunogenicity and effectiveness in the
Gabiria Pastore, Jacopo Polvere, Fabio Fiorino, Simone Lucchesi, Giorgio Montesi, Ilaria Rancan, Sara Zirpoli, Arianna Lippi, Miriam Durante, Massimiliano Fabbiani, Mario Tumbarello, Francesca Montagnani, Donata Medaglini, Annalisa Ciabattini   +13 more
doaj   +1 more source

A Comparison of the Immunogenicity and Safety of an Additional Heterologous versus Homologous COVID-19 Vaccination among Non-Seroconverted Immunocompromised Patients after a Two-Dose Primary Series of mRNA Vaccination: A Systematic Review and Meta-Analysis

This systematic review and meta-analysis aimed to compare the immunogenicity and safety of an additional heterologous (viral vector) versus homologous (mRNA) COVID-19 vaccine dose among non-seroconverted immunocompromised patients after a two-dose ...
Tavitiya Sudjaritruk, Karan Srisurapanont, Chatchaya Nangsue   +2 more
core   +1 more source